OSTX on NYSE
OS Therapies Inc
American pharmaceutical preparations company based in Grasonville. Summary from the record
Price unavailable
Last updated Oct 19, 2026.
Overview
- TickerOSTX on NYSE1
- IndustryPharmaceutical Preparations1
- HeadquartersRockville, Maryland1
- Incorporated inDE2
- Business address15825 Shady Grove Road, Suite 135, Rockville, Md 208502
- Filer category, Emerging growth company2
- Legal formCorporation
See how the biggest companies compare on our leaderboards
Medicines Agency (EMA) regarding the clinical and biomarker data for OST-HER2 in recurrent, fully resected pulmonary metastatic Osteosarcoma.3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development | $16.4M | $2.8M |
| General and administrative | $12.3M | $4.0M |
| Loss from operations | -$28.7M | -$6.8M |
| Interest income | $249 | |
| Interest expense | -$2.1M | |
| Non-operating income | $34.0K | |
| Non-operating expenses | -$1.5M | -$51.2K |
| Change in fair value of warrant liability | $1.4M | |
| TOTAL OTHER INCOME/EXPENSE | -$48.1K | -$2.1M |
| NET LOSS | -$28.8M | -$8.9M |
| Cumulative Series A preferred stock dividend requirement | -$31.2K | |
| NET LOSS available to common shareholders | -$28.8M | -$8.9M |
| Weighted average # of shares (in Shares) | 29.3M shares | 7.0M shares |
| Basic loss per common share outstanding (in Dollars per share) | -$0.98 | -$1.28 |
| Diluted loss per common share outstanding (in Dollars per share) | -$0.98 | -$1.28 |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash | $269.8K | $5.5M | |
| Prepaid expenses | $63.1K | ||
| Total Current Assets | $332.9K | $5.5M | |
| Fixed assets (net) | $2.5K | $5.3K | |
| Patent (net of amortization) | $6.5M | ||
| Total-Long Term Assets | $6.5M | $5.3K | |
| TOTAL ASSETS | $6.8M | $5.5M | |
| Accounts payable | $9.9M | $1.7M | |
| Accrued expenses | $1.4M | $521.0K | |
| Accrued payroll and payroll taxes related party | $36.8K | $97.3K | |
| Accrued payroll and payroll taxes | $1.3K | ||
| Preferred dividends payable | $375.0K | $375.0K | |
| Warrant liability | $2.0M | ||
| Total Current Liabilities | $11.8M | $4.6M | |
| TEDCO grant | $100.0K | $100.0K | |
| Total Long-Term Liabilities | $100.0K | $100.0K | |
| Total Liabilities | $11.9M | $4.7M | |
| Series A Convertible Preferred Stock, par value $0.001, 2,500,000 shares authorized; 392,500 and 1,775,750 issued and outstanding, respectively | $1.1M | $4.1M | |
| Total Mezzanine Equity | $1.1M | $4.1M | |
| Common Stock A, par value $0.001, 150,000,000 shares authorized; 37,113,082 and 20,869,908 issued and outstanding, respectively | $37.1K | $20.9K | |
| Additional paid-in capital | $61.1M | $35.1M | |
| Accumulated deficit | -$67.2M | -$38.4M | |
| Total Stockholders Deficit | -$6.1M | -$3.3M | -$24.0M |
| TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS DEFICIT | $6.8M | $5.5M | |
| Common stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in Shares) | 150.0M shares | 150.0M shares | |
| Common stock, shares issued (in Shares) | 37.1M shares | 20.9M shares | |
| Common stock, shares outstanding (in Shares) | 37.1M shares | 20.9M shares | |
| Preferred Stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Preferred Stock, shares authorized (in Shares) | 5.0M shares | 5.0M shares | |
| Preferred Stock, shares issued (in Shares) | 0 shares | 0 shares | |
| Preferred Stock, shares outstanding (in Shares) | 0 shares | 0 shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash | $269.8K | $5.5M | |
| Prepaid expenses | $63.1K | ||
| Total Current Assets | $332.9K | $5.5M | |
| Fixed assets (net) | $2.5K | $5.3K | |
| Patent (net of amortization) | $6.5M | ||
| Total-Long Term Assets | $6.5M | $5.3K | |
| TOTAL ASSETS | $6.8M | $5.5M | |
| Accounts payable | $9.9M | $1.7M | |
| Accrued expenses | $1.4M | $521.0K | |
| Accrued payroll and payroll taxes related party | $36.8K | $97.3K | |
| Accrued payroll and payroll taxes | $1.3K | ||
| Preferred dividends payable | $375.0K | $375.0K | |
| Warrant liability | $2.0M | ||
| Total Current Liabilities | $11.8M | $4.6M | |
| TEDCO grant | $100.0K | $100.0K | |
| Total Long-Term Liabilities | $100.0K | $100.0K | |
| Total Liabilities | $11.9M | $4.7M | |
| Series A Convertible Preferred Stock, par value $0.001, 2,500,000 shares authorized; 392,500 and 1,775,750 issued and outstanding, respectively | $1.1M | $4.1M | |
| Total Mezzanine Equity | $1.1M | $4.1M | |
| Common Stock A, par value $0.001, 150,000,000 shares authorized; 37,113,082 and 20,869,908 issued and outstanding, respectively | $37.1K | $20.9K | |
| Additional paid-in capital | $61.1M | $35.1M | |
| Accumulated deficit | -$67.2M | -$38.4M | |
| Total Stockholders Deficit | -$6.1M | -$3.3M | -$24.0M |
| TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS DEFICIT | $6.8M | $5.5M | |
| Common stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in Shares) | 150.0M shares | 150.0M shares | |
| Common stock, shares issued (in Shares) | 37.1M shares | 20.9M shares | |
| Common stock, shares outstanding (in Shares) | 37.1M shares | 20.9M shares | |
| Preferred Stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Preferred Stock, shares authorized (in Shares) | 5.0M shares | 5.0M shares | |
| Preferred Stock, shares issued (in Shares) | 0 shares | 0 shares | |
| Preferred Stock, shares outstanding (in Shares) | 0 shares | 0 shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$28.8M | -$8.9M |
| Depreciation and amortization expense | $363.1K | $2.8K |
| Amortization of debt discounts issuance and warrants | $1.4M | |
| Shares issued for services | $25.0K | |
| Shares issued for interest expense | $8.5K | |
| Change in value of warrant liabilities | -$1.4M | |
| Commitment shares issued for equity line of credit | $568.2K | |
| Common shares issuance for services | $595.8K | |
| Stock-based compensation | $4.3M | $268.3K |
| Amortization of non-cash prepaids | $1.0M | |
| Accounts payable | $8.3M | -$1.1M |
| Accrued expenses | $894.0K | $358.5K |
| Accrued interest on convertible notes | $613.6K | |
| Accrued Payroll and payroll taxes | -$59.2K | -$48.4K |
| Net cash used in operating activities | -$14.2M | -$7.3M |
| Patent License Acquisition | -$466.4K | |
| Net cash used in investing activities | -$466.4K | |
| Prepaid warrants (net of fees) | $530.2K | |
| Common stock issuance (net of fees) | $7.9M | |
| Short-term borrowings | $250.0K | |
| Short-term loan repayments | -$250.0K | |
| Sale of preferred stock | $1.1M | $6.0M |
| Initial public offering (net of fees) | $5.2M | |
| Net proceeds from conversion of debt A, B, C, D, E & F | $1.5M | |
| Net cash provided by financing activities | $9.4M | $12.8M |
| Net change in cash | -$5.3M | $5.5M |
| Discount on notes payable redemption premium | $750.5K | |
| Dividends payable | $31.2K | |
| Deemed dividend on Series A convertible preferred stock | $2.0M | |
| Mezzanine equity conversion (net of costs) | $3.7M | |
| Conversion of preferred stock to common stock | $1.3K | |
| Amortization of deferred offering costs | $751.0K | |
| Conversion of convertible notes into common stock | $24.8M | |
| Conversion of warrants into common stock | $411 | |
| Issuance of common stock to investor advisor settlement | $320 | |
| Conversion of make-whole liability to common stock | $130.0K | |
| Clawback of common stock for over issuance | -$670 | |
| Common stock issued for patent purchase | $6.4M | |
| Reclassification of warrants liability to equity | $878.2K | |
| Shares issued for prepaid services | $1.1M |
No quarter-by-quarter statement was filed.
Leadership
Who has led OS Therapies Inc, and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
2025
- Chief executive officerPaul A. Romness Aug 1, 2024 to now8
- PresidentPaul A. Romness Aug 1, 2024 to now8
- Chief financial officerChristopher P. Acevedo Aug 1, 2024 to now9
Board members and other officers (10)
- OfficerRobert Petit Aug 1, 2024 to now10
- Board memberCraig Eagle Jul 23, 2026 to now11
- Board memberKarim Galzahr Feb 6, 2025 to now12
- Board memberColin Goddard Aug 1, 2024 to now13
- Board memberJoacim Borg Aug 1, 2024 to Aug 1, 202414
- Board memberJohn Ciccio Aug 1, 2024 to now15
- Board memberPaul A. Romness Aug 1, 2024 to now8
- Board memberTheodore F. Search Aug 1, 2024 to now16
- Board memberAvril Suzette McKean-Dieser Oct 29, 2024 to now17
- Board memberOlivier R. Jarry Oct 29, 2024 to now18
Named in SEC Form D filings
People the company listed in its private-offering notices.
Timeline
- Aug 1, 2024New chief executive Paul A. Romness becomes CEO8
Filings
229 filings to the SEC since October 2021: 2 annual reports, 8 quarterly reports, 40 major events, 50 insider forms, 9 large holders, 9 private raises, 111 other. The latest 20:
- Oct 5, 20263 EDGAR
- Oct 5, 20263 EDGAR
- Oct 5, 20268-K CURRENT REPORT EDGAR
- Sep 21, 2026S-8 REGISTRATION STATEMENT EDGAR
- Sep 10, 20268-K CURRENT REPORT EDGAR
- Sep 10, 2026424B7 PROSPECTUS SUPPLEMENT EDGAR
- Sep 9, 20268-K CURRENT REPORT EDGAR
- Aug 25, 2026D EDGAR
- Aug 21, 20268-K CURRENT REPORT EDGAR
- Aug 21, 2026424B5 PROSPECTUS SUPPLEMENT EDGAR
- Aug 14, 202610-Q QUARTERLY REPORT EDGAR
- Aug 12, 20268-K CURRENT REPORT EDGAR
- Aug 6, 20268-K CURRENT REPORT EDGAR
- Aug 6, 2026424B5 PROSPECTUS SUPPLEMENT EDGAR
- Jul 29, 20268-K CURRENT REPORT EDGAR
- Jul 24, 2026ARS EDGAR
- Jul 24, 2026DEFA14A DEFINITIVE ADDITIONAL MATERIALS EDGAR
- Jul 24, 2026DEF 14A PROXY STATEMENT EDGAR
- Jul 23, 20263 EDGAR
- Jul 16, 2026D EDGAR
The 229 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
5 open-market trades by officers, directors and large owners since October 2021: 0 buys and 5 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| May 7, 2025 | Auerbach Shalom | Sale | 82,000 | $2.00 | $164.0K | Form 4 |
| Apr 10, 2025 | Auerbach Shalom | Sale | 10,000 | $1.39 | $13.9K | Form 4 |
| Apr 9, 2025 | Auerbach Shalom | Sale | 50,012 | $1.35 | $67.5K | Form 4 |
| Feb 14, 2025 | Einodmil LLC | Sale | 100,000 | $2.84 | $284.0K | Form 4 |
| Jan 15, 2025 | Auerbach Shalom | Sale | 16,720 | $6.74 | $112.7K | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
Money raised
Private offerings the company reported to the SEC on Form D.
- Aug 10, 2026Raised $5 million in a private offering of securities Form D: $10 million offered in all Form D
- Jun 30, 2026Raised $1.6 million in a private offering of debt Form D: $9.2 million offered in all Form D
- Mar 4, 2026Raised $2 million in a private offering of debt Form D: 9 investors so far Form D
- Jan 14, 2026Raised $3.5 million in a private offering of equity Form D: $7.5 million offered in all Form D
- Sep 2, 2025Raised $3.8 million in a private offering of equity Form D: 10 investors so far Form D
- Jun 23, 2025Raised $4.2 million in a private offering of equity Form D: 27 investors so far Form D
- Dec 31, 2024Raised $7.1 million in a private offering of equity Form D: $10 million offered in all Form D
- Dec 8, 2023Raised $700,000 in a private offering of securities Form D: $2 million offered in all Form D
- Nov 16, 2022Raised $2 million in a private offering of equity Form D: 11 investors so far Form D
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 29. Change is in shares since the quarter before.
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10SEC EDGARRobert Petit, Officer
- 11SEC EDGARCraig Eagle, Board member
- 12SEC EDGARKarim Galzahr, Board member
- 13SEC EDGARColin Goddard, Board member
- 14SEC EDGARJoacim Borg, Board member
- 15SEC EDGARJohn Ciccio, Board member
- 16SEC EDGARTheodore F. Search, Board member
- 17
- 18SEC EDGAROlivier R. Jarry, Board member
- 19
- 20
- 21
- 22